Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Anti-Inflammatory Drugs May Treat Some Aggressive Tumors

By BiotechDaily International staff writers
Posted on 10 Jul 2014
Print article
Image: A mouse mammary gland missing the tumor-suppressor p53 shows expression of ARF (green), now known for a backup role in protecting cells from becoming cancerous. If both p53 and ARF are mutated, the tumors that form are aggressive and may benefit from treatment with anti-inflammatory drugs called JAK inhibitors, currently prescribed for rheumatoid arthritis (Photo courtesy of Raleigh Kladney).
Image: A mouse mammary gland missing the tumor-suppressor p53 shows expression of ARF (green), now known for a backup role in protecting cells from becoming cancerous. If both p53 and ARF are mutated, the tumors that form are aggressive and may benefit from treatment with anti-inflammatory drugs called JAK inhibitors, currently prescribed for rheumatoid arthritis (Photo courtesy of Raleigh Kladney).
New research raises the possibility that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis.

By studying triple-negative breast cancer, researchers from Washington University School of Medicine in St. Louis (MO, USA) found that some aggressive tumors rely on an antiviral pathway that seems to fuel the inflammation process, widely recognized for roles in rheumatoid arthritis, cancer, and other inflammatory diseases.

The investigators reported their findings in the June 26, 2014, issue of the journal Cell Reports. Until now, even though ARF was known to be expressed in some tumors with mutated p53, ARF largely was thought to be nonfunctional in this scenario. But the investigators showed that in the absence of p53, ARF actually protects against even more aggressive tumor formation.

“It’s probably inaccurate to say that ARF completely replaces p53, which is a robust tumor suppressor with multiple ways of working,” said senior author Jason D. Weber, PhD, an associate professor of medicine. “But it appears the cell has set up a sort of backup system with ARF. It’s not surprising that these are the two most highly mutated tumor suppressors in cancer. Because they’re backing one another up, the most aggressive tumors form when you lose both.”

Related Links:

Washington University School of Medicine in St. Louis



Print article

Channels

Genomics/Proteomics

view channel
Image: A confocal microscopy image of human fibroblasts derived from embryonic stem cells. The nuclei appear in blue, while smaller and more numerous mitochondria appear in red (Photo courtesy of Dr. Shoukhrat Mitalipov, Oregon Health & Science University).

Stem Cells Derived from Older Individuals May Carry Unsafe Mitochondrial DNA Mutations

Induced pluripotent stem cells (iPSCs) derived from the skin fibroblasts of older individuals have a likelihood of harboring mitochondrial DNA mutations, which may render them unfit for clinical applications.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

DNA Synthesis Specialists Acquire Advanced Software Design Capabilities

An American biotech firm that develops and produces synthetic DNA has established an international presence by purchasing an Israeli genetic design software company. Twist Bioscience Corporation (San Francisco, CA, USA), a company specializing in rapid, high-quality DNA synthesis, announced that Genome Compiler Corporation... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.